Hologic (HOLX) Stock Forecast & Price Target

$69.73 -0.24 (-0.34%)

As of 01/17/2025 04:00 PM Eastern

Hologic - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
7

Buy
9

Based on 16 Wall Street analysts who have issued ratings for Hologic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 7 have given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for HOLX.

Consensus Price Target

$88.92
27.52% Upside

According to the 16 analysts' twelve-month price targets for Hologic, the average price target is $88.92. The highest price target for HOLX is $95.00, while the lowest price target for HOLX is $82.00. The average price target represents a forecasted upside of 27.52% from the current price of $69.73.

Get the Latest News and Ratings for HOLX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hologic and its competitors.

HOLX Analyst Ratings Over Time

Type	Current Forecast 1/21/24 to 1/20/25	1 Month Ago 12/22/23 to 12/21/24	3 Months Ago 10/23/23 to 10/22/24	1 Year Ago 1/21/23 to 1/21/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)
Hold	7 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$88.92	$89.50	$87.50	$87.18
Forecasted Upside	27.52% Upside	24.91% Upside	7.26% Upside	18.58% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

HOLX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HOLX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Hologic Stock vs. The Competition

Type	Hologic	Medical Companies	S&P 500
Consensus Rating Score	2.63	2.82	2.52
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	27.52% Upside	24,741.15% Upside	12.44% Upside
News Sentiment Rating	Neutral News See Recent HOLX News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/13/2025	William Blair 1 of 5 stars		Reiterated Rating	Outperform
1/13/2025	Morgan Stanley 3 of 5 stars	Tejas Savant Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$84.00 ➝ $82.00	+16.41%
1/13/2025	Needham & Company LLC 2 of 5 stars	Mike Matson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $90.00	+25.52%
12/13/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Schenkel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Peer Perform
12/10/2024	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	N. Ty Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/10/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$85.00	+12.15%
11/5/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$84.00 ➝ $90.00	+12.60%
11/5/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $87.00	+8.85%
11/5/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$93.00 ➝ $95.00	+18.85%
11/5/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Sector Perform ➝ Sector Perform	$86.00 ➝ $89.00	+11.72%
Get the Latest News and Ratings for HOLX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.
11/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$92.00 ➝ $94.00	+17.79%
10/8/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$95.00 ➝ $90.00	+12.67%
10/1/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	In-Line ➝ In-Line	$78.00 ➝ $82.00	+1.61%
10/1/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$95.00 ➝ $85.00	+4.35%
7/30/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Carrico Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$92.00 ➝ $92.00	+12.81%
5/9/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$89.00 ➝ $95.00	+24.48%
8/1/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$94.00 ➝ $86.00	+8.29%
2/2/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$86.00 ➝ $95.00	+14.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:54 PM ET.

Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 12, 2025. Please send any questions or comments about these Hologic pros and cons to contact@marketbeat.com.

Hologic
Bull Case

Here are some ways that investors could benefit from investing in Hologic, Inc.:

Hologic, Inc. reported a strong earnings per share (EPS) of $1.01 for the latest quarter, meeting analysts' expectations, which indicates solid financial performance and stability.
The company achieved a revenue of $987.90 million for the quarter, surpassing the consensus estimate of $978.25 million, reflecting effective business operations and demand for its products.
With a net margin of 19.59%, Hologic, Inc. demonstrates efficient cost management and profitability, which can be attractive to investors looking for financially sound companies.
The current stock price is $71.65, which may present a buying opportunity for investors, especially considering the average price target of $89.50 set by analysts, suggesting potential upside.
Analysts have a positive outlook on Hologic, Inc., with a consensus rating of "Moderate Buy," indicating confidence in the company's future performance and growth prospects.

Hologic
Bear Case

Investors should be bearish about investing in Hologic, Inc. for these reasons:

Insider selling activity, such as the COO selling 24,856 shares, may raise concerns about the company's future prospects and could indicate a lack of confidence from management.
The stock has experienced volatility, with a 52-week low of $70.36, which may deter risk-averse investors looking for stable investments.
Despite recent revenue growth of 4.5% year-over-year, the overall market conditions and competition in the medical equipment sector could pose challenges to sustained growth.
The company's debt-to-equity ratio of 0.49 suggests a moderate level of debt, which could impact financial flexibility and increase risk during economic downturns.
Recent analyst downgrades, such as Mizuho lowering their target price from $90.00 to $87.00, may signal caution regarding the stock's short-term performance.

HOLX Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Hologic is $88.92, with a high forecast of $95.00 and a low forecast of $82.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 7 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HOLX shares.
: According to analysts, Hologic's stock has a predicted upside of 27.52% based on their 12-month stock forecasts.
: Over the previous 90 days, Hologic's stock had 1 upgrade by analysts.
: Hologic has been rated by research analysts at BNP Paribas, Jefferies Financial Group, JPMorgan Chase & Co., Mizuho, Morgan Stanley, Needham & Company LLC, Raymond James, Royal Bank of Canada, UBS Group, William Blair, and Wolfe Research in the past 90 days.
: Analysts like Hologic less than other "medical" companies. The consensus rating score for Hologic is 2.63 while the average consensus rating score for "medical" companies is 2.82. Learn more on how HOLX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:HOLX) was last updated on 1/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hologic (HOLX) Stock Forecast & Price Target